Некоторые аспекты лечения взрослых больных инфекцией, вызванной вирусом Эпштейна-Барр


Цитировать

Полный текст

Аннотация

Аннотация. В обзоре проанализированы основные аспекты лечебной тактики ведения больных с различными формами инфекции, вызванной вирусом Эпштейна-Барр. На основании обширных данных литературы, опубликованных за последние 20 лет, приведены практические рекомендации.

Полный текст

Некоторые аспекты лечения взрослых больных инфекцией, вызванной вирусом Эпштейна-Барр. - Аннотация. В обзоре проанализированы основные аспекты лечебной тактики ведения больных с различными формами инфекции, вызванной вирусом Эпштейна-Барр. На основании обширных данных литературы, опубликованных за последние 20 лет, приведены практические рекомендации.
×

Об авторах

Н Д Ющук

МГМСУ им. А.И. Евдокимова, Москва

Email: shes.irin@mtu-net.ru

И В Шестакова

МГМСУ им. А.И. Евдокимова, Москва

Email: shes.irin@mtu-net.ru

Список литературы

  1. Epstein M.A. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964; 1: 702.
  2. Henle G., Henle W., Diehl V. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA 1968; 59 (1): 94-101.
  3. Sawyer R.N., Evans A.S., Niederman J.C., McCollum R.W. Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis. J Infect Dis 1971; 123 (3): 263-270.
  4. Cohen J.I. Epstein-Barr virus infection. New Engl J Med 2000; 343 (7): 481-491.
  5. Foerster J. Infectious mononucleosis. In: Lee. Wintrobe's Clinical Hematology. 10th ed. 1999: 1926-1955.
  6. Li Z.Y., Lou J.G., Chen J. Analysis of primary symptoms and disease spectrum in Epstein-Barr virus infected children. Zhonghua Er Ke Za Zhi 2004; 42 (1): 20-22.
  7. Grotto I., Mimouni D., Huerta M. et al. Clinical and laboratory presentation of EBV positive infectious mononucleosis in young adults Epidemiol Infect 2003; 131 (1): 683-689.
  8. Поляков В.Е., Лялина В.Н., Воробьева М.Л. Инфекционный мононуклеоз (болезнь Филатова) у детей и подростков. Эпидемиол и инфекц бол 1998; 6: 50-54.
  9. Gershburg E., Pagano J.S. Epstein-Barr infections: prospects for treatment. J Antimicrob Chemother 2005; 56 (2): 277-281.
  10. Behrman R.E., Kliegman R.M., Jenson H.B. (ed). Nelson textbook of pediatrics, 17th еd. 2004: 2615-2619.
  11. Okano M. Epstein-Barr virus infecion and its role in the expanding spectrum of human diseases. Acta Paediatr 1998; 87 (1): 11-18.
  12. Pagano J.S. Viruses and lymphomas. N Engl J Med 2002; 347 (2): 78-79.
  13. Lande M.B. Immune complex disease associated with Epstein-Barr virus infectious mononucleosis. Pediatr Nephrol 1998; 12 (8): 651-653.
  14. Cohen J.I., Kimura H., Nakamura S. et al. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008 Ann Oncol 2009; 20 (9): 1472-1482.
  15. Faulkner G.C., Krajewski A.S., Crawford A. The ins and outs of EBV infеction. Trends Microbiol 2000; 8: 185-189.
  16. Chaganti S., Ma C.S., Bell A.I. et al. Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients. Blood 2008; 112 (3): 672-679.
  17. Crawford D.H., Macsween K.F., Higgins C.D. et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis 2006; 43: 276-282.
  18. Gulley M.L., Glaser S.L., Craig F.E. et al. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol 2002; 117: 259-267.
  19. Hjalgrim H., Askling J., Rostgaard K. et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003; 349: 1324-1332.
  20. Liebowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol 1994; 21 (3): 376-381.
  21. Hanto D.W. Classification of Epstein-Barr virus-associated post transplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995; 46: 381-394.
  22. Tosato G., Taga K., Angiolillo A.L., Sgadari C. Epstein-Barr virus as an agent of haematological disease. Baillieres Clin Haematol 1995; 8 (1): 165-199.
  23. Schooley R.T. Epstein-Barr virus (infectious mononucleosis). In: Mandell. Principles and Practice of Infectious Diseases. 5th ed. 2000: 1599-1608.
  24. Малашенкова И.К., Дидковский Н.А., Говорун В.М., Ильина Е.Н. Роль вируса Эпштейна-Барр в развитии синдрома хронической усталости и иммунной дисфункции. Int J Immunorehabilitat 2000; 1: 102-111.
  25. Никольский И.С., Юрченко В.Д., Никольская К.И. Характеристика активной хронической Эпштейна-Барр-вирусной инфекции: клинико-иммунологический синдром. Совр инфекц 2003; 3: 60-62.
  26. Anderson J. Clinical and immunological considerations in Epstein-Barr virus associated diseases. Scand J Infect Dis 1996; Suppl. 100: 72-82.
  27. Yamashita S., Murakami C., Izumi Y. Severe chronic active Epstein- Barr virus infection accompanied by virus-associated hemophagocytic syndrome, cerebellar ataxia and encephalitis. Psychiatry Clin Neurosci 1998; 52 (4): 449-452.
  28. Lekstron-Himes J.A., Dale J.K., Kingma D.W. Periodic illness associated with Epstein-Barr virus infection. Clin Infect Dis 1996; 22 (1): 22-27.
  29. Schooley R.T., Carey R.W., Miller G. et al. Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. Ann Intern Med 1986; 104 (5): 636-643.
  30. Maakaroun N.R., Moanna A., Jacob J.T., Albrecht H. Viral infections associated with haemophagocytic syndrome. Rev Med Virol 2010; 20 (2): 93-105.
  31. Manika K., Alexiou-Daniel S., Papakosta D. et al. Epstein-Barr virus DNA in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2007; 24 (2): 134-140.
  32. Candy B., Chalder T., Cleare A.J. et al. Predictors of fatigue following the onset of infectious mononucleosis. Psychol Med 2003; 33 (5): 847-855.
  33. Katz B.Z., Shiraishi Y., Mears C.J. et al. Chronic fatigue syndrome after infectious mononucleosis in adolescents. Pediatrics 2009; 124 (1): 189-193.
  34. Straus S.E. The chronic mononucleosis syndrome J Infect Dis 1988; 157 (3): 405-412.
  35. Tobi M., Straus S.E. Chronic mononucleosis a legitimate diagnosis Postgrad Med 1988; 83 (1): 69-78.
  36. Краснов В.В. Инфекционный мононуклеоз. Клиника, диагностика, современные принципы лечения. СПб: Н. Новгород 2003.
  37. Ebell M.H. Epstein-Barr Virus Infectious Mononucleosis Fam. Physician 2004; 70 (7): 1279-1287.
  38. Okano M., Gross G. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients. Expert Rev Anti Infect Ther 2007; 5 (3): 403-413.
  39. Dalrymple W. Infectious mononucleosis. Relation of bed rest and activity to prognosis. Postgrad Med 1964; 35: 345-349.
  40. Кудин А.П. Эта "безобидная" вирус Эпштейна-Барра инфекция. Часть 2. Острая ВЭБ-инфекция: эпидемиология, клиника, диагностика, лечение. Мед новости 2006; 8: 25-31.
  41. Vendelbo J.L., Lildholdt T., Bende M. et al. Infectious mononucleosis treated by an antihistamine: a comparison of the efficacy of ranitidine (Zantac) vs placebo in the treatment of infectious mononucleosis. Clin Otolaryngol 1997; 22: 123-125.
  42. Боковой Ф.Г., Лыкова Е.А., Дегтярева В.А. и др. Лечение острых форм инфекционного мононуклеоза у детей в стационаре. Эпидемиол и инфекц бол 2007; 1: 53-56.
  43. Fota-Markowcka H. Profile of microorganisms isolated in nasopharyngeal swabs from the patients with acute infectious mononucleosis. Wiad Lek 2002; 55 (3-4): 150-157.
  44. Tynell E., Aurelius E., Brandell A. et al. Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. J Infect Dis 1996; 174: 324-331.
  45. Roy M., Bailey B., Amre D.K. et al. Dexamethasone for the treatment of sore throat in children with suspected infectious mononucleosis: a randomized, double-blind, placebo-controlled, clinical trial. Archiv Pediatric Adolescent Med 2004; 158: 250-254.
  46. Epstein-Barr virus and infectious mononucleosis. Accessed online August 16, 2004, at: http://www.cdc.gov/ncidod/diseases/ebv.htm
  47. Казмирчук В.Е., Мальцев Д.В. Рекомендации по лечению герпесвирусных заболеваний человека. Врачу-практику 2012: 5 (91); IX/X.
  48. Furman P.A., de Miranda P., St. Clair M.H. et al. Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrob Agents Chemother 1981; 20: 518-524.
  49. St Clair M.H., Furman P.A., Lubbers C.M. et al. Inhibition of cellular alpha and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir. Antimicrob Agents Chemother 1980; 18: 741-745.
  50. Meerbach A. Inhibitory effects of novel nucleoside and nucleotide analogues on Epstein-Barr virus replication. Antivir Chem Chemother 1998; 9 (3): 275-282.
  51. Torre D., Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis 1999; 31: 543-547.
  52. Van der Horst C., Joncas J., Ahronheim G. et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J Infect Dis 1991; 164: 788-792.
  53. Wu Y., Luo C., Lu Z. et al. Curative effect of interfon-alpha in children with infectious mononucleosis. Hua Xi Yi Ke Da Xue Xue Bao 1996; 27 (1): 82-84.
  54. Sakai Y., Ohga S., Tonegawa Y. et al. Interferon-alpha therapy for chronic active Epstein-Barr virus infection: potential effect on the development of T-lymphoproliferative disease. J Pediatr Hematol Oncol 1998; 20 (4): 342-346.
  55. O'Brien S., Bernert R.A., Logan J.L., Lien Y.H. Remission of posttransplant lymphoproliferative disorder after interferon alfa therapy. J Am Soc Nephrol 1997; 8 (9): 1483-1489.
  56. Winston D.J., Eron L.J., Ho M. et al. Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer. Am J Med 1988; 85 (2): 147-151.
  57. Toraldo R., D'Avanzo M., Tolone C. et al. Effect of interferon-alpha therapy in a patient with common variable immunodeficiency and chronic Epstein-Barr virus infection. Pediatr Hematol Oncol 1995; 12 (5): 489-493.
  58. Okano M., Pirruccello S.J., Grierson H.L. et al. Immunovirological studies of fatal infectious mononucleosis in a patient with X-linked lymphoproliferative syndrome treated with intravenous immunoglobulin and interferon-alpha. Clin Immunol Immunopathol 1990; 54 (3): 410-408.
  59. Ferrara G., Zumla A., Maeurer M. Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections. Am J Med 2012; 125 (10): 1036.e1-1036.e8.
  60. Ma C., Wong C.K., Wong B.C. et al. Cytokine responses in a severe case of glandular fever treated successfully with foscarnet combined with prednisolone and intravenous immunoglobulin. J Med Virol 2009; 81 (1): 99-105.
  61. Казмірчук В.Є., Мірошникова М.І. Лікування ускладнених форм Епштейна-Барр вірусної інфекції. Сучасні інфекції 2002; 4: 8-12.
  62. Филатов Л.Б., Пивник А.В. Ритуксимаб в лечении аутоиммунных цитопений. Совр онкол 2008; 2: 1-20.
  63. Gong Q., Ou Q., Ye Sh. et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-826.
  64. Fernαndez-Ruiz M., San-Juan R., Aguado J.M. Epstein-Barr virus DNAemia and infectious complications after preemptive rituximab treatment. Transplantation 2013; 95 (3): e13.
  65. Petropoulou A.D., Porcher R., Peffault de Latour R. et al. Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation. Transplantation 2012; 94 (8): 879-883.
  66. Cohen J.I., Jaffe E.S., Dale J.K. et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood 2011; 117 (22): 5835-5849.
  67. Демиденко Т.Д., Ермакова Н.Г. Основы реабилитации неврологических больных. СПб: ФОЛИАНТ 2004; 304.
  68. Мохорт Т.В. Возможности коррекции и профилактики синдрома хронической усталости. Мед новости 2003; 2: 71-78.
  69. Albrecht F. Chronic fatigue syndrome. J Am Acad Child Adolesc Psychiatry 2000; 39 (7): 808-809.
  70. Rea T.D., Russo J.E., Katon W. et al. Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. J Am Board Fam Pract 2001; 14: 234-242.
  71. Candy B., Chalder T., Cleare A.J. et al. Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review. Br J Gen Pract 2002; 52: 844-851.
  72. Epstein M.A., Morgan A.J., Finerty S. et al. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 1985; 318: 287-289.
  73. Gu S.-Y., Huang T.-M., Ruan L. et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995; 84: 171-177.
  74. Jackman W.T., Mann K.A., Hoffmann H.J., Spaete R.R. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for EBV subunit vaccine. Vaccine 1999; 17: 660-668.
  75. Khanna R., Moss D.J., Burrows S.R. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 1999; 170: 49-64.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2014

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Адрес издателя

  • 127055, г. Москва, Алабяна ул., 13, корп.1

Адрес редакции

  • 127055, г. Москва, Алабяна ул., 13, корп.1

По вопросам публикаций

  • +7 (926) 905-41-26
  • editor@ter-arkhiv.ru

По вопросам рекламы

  • +7 (495) 098-03-59

 

  


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах